Inhaled sevoflurane may promote progression of amnestic mild cognitive impairment: A prospective, randomized parallel-group study

American Journal of the Medical Sciences

Volumn 345, Issue 5, 2013, Pages 355-360

  Liu, Yongzhe ^a   Pan, Ningling ^a   Ma, Yaqun ^a   Zhang, Shengshuo ^a   Guo, Wenzhi ^a   Li, Haihong ^a   Zhou, Jingli ^a   Liu, Gang ^a   Gao, Minglong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

AD; aMCI; Progressive MCI; Sevoflurane

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; LIDOCAINE; PROPOFOL; SEVOFLURANE; TAU 181 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE COURSE; EPIDURAL ANESTHESIA; FEMALE; HUMAN; INHALATION; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; OUTPATIENT; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SPINE SURGERY;

EID: 84876868366     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31825a674d     Document Type: Article

References (40)

1. Masters CL, Cappai R, Barnham KJ, et al. Molecular mechanisms for Alzheimer's disease: Implications for neuroimaging and therapeutics. J Neurochem 2006;97:1700-25.
2. Mistur R, Mosconi L, Santi SD, et al. Current challenges for the early detection of Alzheimer's disease: Brain imaging and CSF studies. J Clin Neurol 2009;5:153-66.
3. Panza F, D'Introno A, Colacicco AM, et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry 2005;13:633-44.
4. Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med 2010;8:89.
5. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
6. Maccioni RB, Lavados M, Guillón M, et al. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol Aging 2006;27:237-44.
7. Koppel J. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2005;64:766.
8. Selkoe D. Defining molecular targets to prevent Alzheimer's disease. Arch Neurol 2005;62:192-5.
9. Blennow K, Hampel H. Cerebrospinal fluid markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.
10. Shaw L, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-13.
11. Karow DS, McEvoy LK, Fennema-Notestine C, et al. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology 2010;256: 932-42.
12. Jack C, Lowe V, Senjem M, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131(pt 3): 665-80.
13. Gasparini M, Vanacore N, Schiaffini C, et al. A case-control study on Alzheimer's disease and exposure to anesthesia. Neurol Sci 2002;23:11-4.
14. Bohnen N, Warner MA, Kokmen E, et al. Early and midlife exposure to anesthesia and age of onset of Alzheimer's disease. Int J Neurosci 1994;77:181-5.
15. Eckenhoff RG, Johansson JS, Wei H, et al. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 2004;101:703-9.
16. Wei H, Kang B, Wei W, et al. Isoflurane and sevoflurane affect cell survival and BCL-2/BAX ratio differently. Brain Res 2005;1037:139-47.
17. Xie Z, Dong Y, Maeda U, et al. The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology 2006;104:988-94.
18. Xie Z, Dong Y, Maeda U, et al. The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci 2007;27:1247-54.
19. Xie Z, Culley DJ, Dong Y, et al. The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo. Ann Neurol 2008;64:618-27.
20. Dong Y, Zhang G, Zhang B, et al. The common inhalational anesthetic sevoflurane induces apoptosis and increases beta-amyloid protein levels. Arch Neurol 2009;66:620-31.
21. Nasu I, Yokoo N, Takaoka S, et al. The dose-dependent effects of isoflurane on outcome from severe forebrain ischemia in the rat. Anesth Analg 2006;103:413-8.
22. Psychological Research Group. Handbook of clinical memory scale. Beijing, China: Institute of Psychology, Chinese Academy of Sciences; 1996.
23. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-9.
24. Jia JA. Statistics: Texts in applied statistics, 2nd ed. Beijing, China: Qinghua College Publishing Company; 2004.
25. Welge-Lüssen A. Ageing, neurodegeneration, and olfactory and gustatory loss. B-ENT 2009;13:129-32.
26. Musicco M. Gender differences in the occurrence of Alzheimer's disease. Funct Neurol 2009;24:89-92.
27. Perneczky R, Drzezga A, Diehl-Schmid J, et al. Gender differences in brain reserve: An (18)F-FDG PET study in Alzheimer's disease. J Neurol 2007;254:1395-400.
28. Caamaño-Isorna F, Corral M, Montes-Martínez A, et al. Education and dementia: A meta-analytic study. Neuroepidemiology 2006; 26:226-32.
29. Markesbery WR. Neuropathologic alterations in mild cognitive impairment: A review. J Alzheimers Dis 2010;19:221-8.
30. Dimou E, Booij J, Rodrigues M, et al. Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res 2009;6:312-9.
31. Feng CS, Qiu JP, Ma HC, et al. Effect of propofol on synaptic longterm potentiation in hippocampal slices of rats. Zhonghua Yi Xue Za Zhi 2007;87:763-7.
32. Mandal PK, Bhavesh NS, Chauhan VS, et al. NMR investigations of amyloid-β peptide interactions with propofol at clinically relevant concentrations with and without aqueous halothane solution. J Alzheimers Dis 2010;21:1303-9.
33. Xia W. Brain amyloid b protein and memory disruption in Alzheimer's disease. Neuropsychiatr Dis Treat 2010;6:605-11.
34. Hampel H, Goernitz A, Buerger K, et al. Advances in the development of biomarkers for Alzheimer's disease: From CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res Bull 2003;61:243-53.
35. Tarawneh R, Holtzman DM. Biomarkers in translational research of Alzheimer's disease. Neuropharmacology. 2010;59:310-22.
36. Ewers M, Buerger K, Teipel SJ, et al. Multicenter assessment of CSFphosphorylated tau for the prediction of conversion of MCI. Neurology 2007;69:2205-12.
37. Hansson O, Zetterberg H, Buchhave P, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:316-20.
38. Riemenschneider M, Lautenschlager N, Wagenpfeil S, et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002;59:1729-34.
39. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 2006;5:228-34.
40. Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology 2007:69: 631-9.